Cedric White, PharmD candidate 2020, and Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP

In July 2019, the FDA approved darolutamide (Nubeqa, Bayer) for men with prostate cancer that has not spread (ie, nonmetastatic) and no longer responds to medical or surgical treatment that lowers testosterone (ie androgen deprivation therapy).